Zinc and Breast Cancer Survival: A Prospective Cohort Study of Dietary Intake and Serum Levels.


Journal

Nutrients
ISSN: 2072-6643
Titre abrégé: Nutrients
Pays: Switzerland
ID NLM: 101521595

Informations de publication

Date de publication:
22 Jun 2022
Historique:
received: 25 04 2022
revised: 14 06 2022
accepted: 20 06 2022
entrez: 9 7 2022
pubmed: 10 7 2022
medline: 14 7 2022
Statut: epublish

Résumé

Zinc has been suggested to play a role in breast cancer progression; however, no previous study on zinc levels and the potential effect on breast cancer survival has been conducted. This study investigates recurrence-free survival (RFS), breast cancer-specific survival (BCSS) and overall survival (OS) in relation to zinc levels, in serum and diet, overall and stratified for phosphorus and selenium levels. The Malmö Diet and Cancer Study, a prospective population-based cohort in Sweden including 17,035 women, was used to identify breast cancer patients diagnosed in the period 1991-2013. Diet was assessed by a validated modified diet history method. A Cox regression analysis yielded hazard ratios (HRs) with 95% confidence intervals adjusted for potential confounders. Out of 1062 patients with invasive breast cancer, 268 recurrences, 205 breast cancer deaths and 228 deaths from other causes were recorded. No overall associations were seen between zinc and RFS, BCSS or OS. However, in women with a high phosphorus intake, a higher BCSS and OS were seen in zinc intake Q2 to Q4 versus Q1; the adjusted HR was 0.41 (0.23-0.73) and 0.64 (0.41-1.00), respectively. The results indicate that the combination of intermediate/high zinc intake and high phosphorus intake may lead to a better breast cancer survival.

Identifiants

pubmed: 35807763
pii: nu14132575
doi: 10.3390/nu14132575
pmc: PMC9268140
pii:
doi:

Substances chimiques

Phosphorus, Dietary 0
Zinc J41CSQ7QDS

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Swedish Cancer Society
ID : 20 0841 PjF

Références

Nutr Rev. 2014 May;72(5):334-52
pubmed: 24739133
J Cancer Prev. 2019 Sep;24(3):146-154
pubmed: 31624720
Ann Epidemiol. 2004 Mar;14(3):195-201
pubmed: 15036223
J Nutr. 2002 Oct;132(10):3061-6
pubmed: 12368396
Cancer Causes Control. 2021 Aug;32(8):815-826
pubmed: 33914217
J Trace Elem Med Biol. 2019 Dec;56:90-99
pubmed: 31442959
Cancer Sci. 2007 May;98(5):692-7
pubmed: 17359283
J Clin Epidemiol. 2009 Nov;62(11):1202-9
pubmed: 19364635
J Epidemiol. 2002 Jan;12(1):14-21
pubmed: 11848180
Eur J Epidemiol. 2017 Sep;32(9):765-773
pubmed: 28983736
Br J Nutr. 2011 Jan;105(1):123-32
pubmed: 20807458
Eur J Cancer Prev. 2001 Dec;10(6):489-99
pubmed: 11916347
Cancer Causes Control. 2014 Aug;25(8):945-57
pubmed: 24825327
Breast Cancer Res Treat. 2021 Sep;189(2):571-583
pubmed: 34224055
Am J Clin Nutr. 2011 Mar;93(3):586-93
pubmed: 21228268
Endocrinology. 2008 Oct;149(10):4912-20
pubmed: 18583420
Sci Rep. 2015 Jul 16;5:12249
pubmed: 26179508
Int J Cancer. 2010 Nov 1;127(9):2159-68
pubmed: 20112341
Eur J Clin Nutr. 1996 Mar;50(3):134-42
pubmed: 8654326
Int J Epidemiol. 1997;26 Suppl 1:S161-73
pubmed: 9126544
J Nutr. 2015 Apr 1;146(4):858S-885S
pubmed: 26962190
Eur J Nutr. 2018 Dec;57(8):2839-2846
pubmed: 29022177
J Intern Med. 1993 Jan;233(1):45-51
pubmed: 8429286
J Nutr. 2018 Aug 1;148(8):1341-1351
pubmed: 29947812
Scand J Public Health. 2002;30(2):103-12
pubmed: 12028859
Mol Carcinog. 2017 Feb;56(2):580-593
pubmed: 27341075
J Nutr. 2000 May;130(5S Suppl):1378S-83S
pubmed: 10801947
Int J Epidemiol. 1998 Oct;27(5):799-807
pubmed: 9839736
Nutrients. 2012 Aug;4(8):875-903
pubmed: 23016122
J Trace Elem Electrolytes Health Dis. 1989 Mar;3(1):55-7
pubmed: 2535321
Epidemiology. 2006 May;17(3):308-14
pubmed: 16570028
Br J Nutr. 2012 Dec 14;108(11):1962-71
pubmed: 23244547
BMC Res Notes. 2014 Apr 07;7:216
pubmed: 24708573

Auteurs

Ylva Bengtsson (Y)

Department of Clinical Sciences Malmö, Lund University, 20213 Malmö, Sweden.
Department of Surgery, Skåne University Hospital, 20501 Malmö, Sweden.

Kamil Demircan (K)

Institute for Experimental Endocrinology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, D-10115 Berlin, Germany.
Berlin Institute of Health (BIH), Biomedical Innovation Academy (BIA), D-10117 Berlin, Germany.

Ann H Rosendahl (AH)

Department of Clinical Sciences Lund, Oncology, Lund University, Skåne University Hospital, 22184 Lund, Sweden.

Signe Borgquist (S)

Department of Oncology, Aarhus University Hospital, Aarhus University, 8200 Aarhus, Denmark.

Malte Sandsveden (M)

Department of Clinical Sciences Malmö, Lund University, 20213 Malmö, Sweden.
Department of Surgery, Skåne University Hospital, 20501 Malmö, Sweden.

Jonas Manjer (J)

Department of Clinical Sciences Malmö, Lund University, 20213 Malmö, Sweden.
Department of Surgery, Skåne University Hospital, 20501 Malmö, Sweden.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH